Feminizing Hormonal Therapy

Mahahalagang Punto

• Karaniwang pinagsasama ng feminizing regimens ang antiandrogen at estrogen para supilin ang testosterone at itaguyod ang female secondary sex characteristics.
• Kabilang sa karaniwang antiandrogen pathways ang spironolactone, gonadotropin-releasing-hormone-gnrh-analogs, o finasteride (kapag hindi angkop ang spironolactone).
• Ang praktikal na follow-up hormone targets ay testosterone na humigit-kumulang 30-100 ng/dL at estradiol na mas mababa sa 200 pg/mL.
• Kabilang sa high-priority risks ang thromboembolic/cardiovascular events sa estrogen at hyperkalemia sa spironolactone.
• Kabilang sa nursing priorities ang baseline risk screening, naka-iskedyul na laboratory surveillance, fertility counseling, at culturally sensitive education.

Regimen Overview

Ang feminizing hormone therapy ay ini-individualize batay sa baseline health, kasalukuyang medications, organ function, risk profile, at treatment goals. Karaniwang staged o pinagsasama ang regimens, at maaaring i-adjust ang dose plans sa paglipas ng panahon upang timbangin ang efficacy at safety.

Maaaring maunang ibigay ang antiandrogen bago ang estrogen, o maaaring sabay na simulan ang antiandrogen at estrogen depende sa protocol at patient factors.

Sanggunian ng ilustrasyon: OpenStax Pharmacology Ch.37.2.

Common Components and Reference Dosing

Component	Typical Adult Dosing Reference	High-Yield RN Notes
Spironolactone	100-200 mg/day PO; may be titrated up to 400 mg/day	I-monitor ang potassium, renal function, at cardiac rhythm risk; repasuhin ang ACE inhibitor/ARB/NSAID interactions at potassium-rich salt substitutes.
Estradiol oral (17-beta-estradiol)	2-4 mg/day PO	I-monitor ang thromboembolic/cardiovascular risk at hormone levels; maaaring pumili ng route alternatives ayon sa risk profile.
Estradiol IM (valerate/cypionate)	Valerate 5-30 mg IM every 2 weeks; cypionate 2-5 mg IM weekly	Tiyakin ang injection-technique teaching at pagsunod sa follow-up labs.
Estradiol transdermal patch	0.1-0.4 mg transdermally twice weekly	Kapaki-pakinabang na non-oral pathway; patibayin ang patch-site rotation at schedule adherence.
Progesterone/progestin	Variable dosing in available protocols	Ang routine use para sa karagdagang breast development ay hindi palaging suportado; dapat individualized ang risk-benefit.
GnRH analog (for example leuprolide)	About 3.75-7.5 mg IM monthly (agent-specific)	Maaaring makabawas sa estrogen o spironolactone requirements; maaaring limitahan ng cost/access at dosing burden ang feasibility.
Finasteride	1-5 mg PO daily	Mas mababa ang antiandrogen potency kaysa spironolactone; kapaki-pakinabang kapag contraindicated o hindi feasible ang spironolactone.

Monitoring Targets and Follow-Up

• I-monitor ang feminizing response at adverse effects bawat 3 buwan sa unang taon, pagkatapos ay humigit-kumulang bawat 6 hanggang 12 buwan.
• I-track ang serum testosterone at estradiol sa follow-up visits.
• Common practical targets:
  • Testosterone about 30-100 ng/dL
  • Estradiol less than 200 pg/mL
• I-monitor ang prolactin at triglycerides sa baseline at sa follow-up.
• I-monitor ang potassium sa mga regimen na may spironolactone.
• I-screen ang bone density bago gamutan sa mga client na may osteoporosis risk; kung hindi, simulan ang screening sa edad na 60 o mas maaga kung nananatiling mababa ang sex-hormone levels.
• Ipagpatuloy ang anatomy-appropriate cancer screening (halimbawa breast at prostate pathways kapag clinically indicated).

Adverse Effects and Contraindication Priorities

• Estrogen-related high-risk events: DVT/PE, stroke, myocardial infarction, hypertension, at lipid/prolactin abnormalities.
• Spironolactone-related high-risk event: Hyperkalemia na may posibleng life-threatening dysrhythmia.
• Finasteride safety: Pregnancy-exposure precautions para sa tablet handling at fetal-risk counseling.
• GnRH analog considerations: Bone-density effects, posibleng QT/cardiac concerns, at evidence gaps sa long-term outcomes.
• Gumamit ng dagdag na pag-iingat sa mga client na may history ng paninigarilyo, obesity, hypertension, renal disease, o thrombotic history.

Immediate Escalation Cues

Agad na mag-escalate para sa chest pain, dyspnea, unilateral leg swelling, severe mood changes, irregular rhythm, seizure-like activity, lip/mouth swelling, o severe muscle cramps.

Nursing Interventions and Client Education

• Kumpletuhin ang baseline assessment: comorbidities, medication reconciliation, at kaugnay na labs/diagnostics bago simulan ang therapy.
• Magbigay ng culturally sensitive at identity-affirming communication sa buong assessment, teaching, at follow-up.
• I-coordinate ang fertility counseling bago ang treatment escalation (halimbawa sperm cryopreservation pathways kapag nais).
• Ituro ang medication names, purpose, dosing schedule, administration route, at major interaction precautions.
• Patibayin ang wellness follow-up at preventive screening adherence habang nasa hormone therapy.
• Iugnay ang mga client sa supportive community at specialty resources kapag kinakailangan.

Related Concepts

• potassium-sparing-diuretics - Spironolactone antiandrogen pathway at hyperkalemia monitoring.
• gonadotropin-releasing-hormone-gnrh-analogs - Alternatibong testosterone-suppression pathway.
• 5-alpha-reductase-inhibitors - Finasteride adjunct/alternative antiandrogen option.
• hormonal-therapy - Estrogen/progestin adverse-effect at black-box context.
• masculinizing-hormonal-therapy - Katumbas na regimen-level framework para sa testosterone-centered pathways.
• sexual-identity-orientation-and-inclusive-nursing-care - Communication at bias-aware care framework.
• transgender-inclusive-breast-and-cervical-cancer-screening - Anatomy-based preventive screening planning.

Self-Check

1. Aling labs at follow-up intervals ang pangunahing safety requirements sa unang taon ng feminizing therapy?
2. Bakit mandatory ang potassium monitoring kapag ginagamit ang spironolactone sa feminizing regimen?
3. Aling urgent symptoms ang nangangailangan ng agarang escalation habang nasa therapy?